FDA CDER Impact Story: Preclinical Research to Achieve Safer Prescribing of Psychoactive Therapeutics for Patients Who Use Opioids – Drug Information Update

The risk of death from opioid use is increased when patients are taking other, non-opioid psychoactive therapeutics with sedative properties. To support safer labeling and prescribing of these non-opioid therapeutics, CDER scientists are developing the capability to screen them for potentially dangerous interactions with opioid drugs. Improved understanding of these interactions can inform better labeling of these drugs so that dangerous and potentially fatal drug combinations are avoided.

To learn more, please visit: FDA CDER Impact Story.